Home Page
Counties
Miami-Dade
33136
AVANTYX, LLC

AVANTYX, LLC - Florida Company Profile

Company Details

Entity Name:	AVANTYX, LLC
Jurisdiction:	FLORIDA
Filing Type:	Florida Limited Liability Co. AVANTYX, LLC is structured as a Limited Liability Company (LLC), a common business structure that offers its members limited liability protection, separating their personal assets from the company's debts and obligations. In Florida, LLCs are governed by Title XXXVI, Chapter 605, Florida Revised Limited Liability Company Act
Status:	Active The business entity is active. This status indicates that the business is currently operating and compliant with state regulations, suggesting a lower risk profile for lenders and potentially better creditworthiness.
Date Filed:	24 Jan 2020 (5 years ago)
Last Event:	LC NAME CHANGE
Event Date Filed:	25 Mar 2022 (3 years ago)
Document Number:	L20000031420
FEI/EIN Number	84-4559630 Federal Employer Identification (FEI) Number assigned by the IRS.
Address:	1951 NW 7TH AVENUE, MIAMI, FL, 33136
Mail Address:	7901 SW 176th Street, Palmetto Bay, FL, 33157, US
ZIP code:	33136
County:	Miami-Dade
Place of Formation:	FLORIDA

Key Officers & Management

Name	Role	Address
Rieger Sandra	Authorized Member	7901 SW 176th Street, Palmetto Bay, FL, 33157
RUIZ BIANCA	Manager	1951 NW 7TH AVENUE, MIAMI, FL, 33136
RIEGER SANDRA PHD	Agent	7901 SW 176th St, Palmetto Bay, FL, 33157

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:

CVYRLJ3H5DL7

CAGE Code:

8JZA3

UEI Expiration Date:

2025-11-13

Business Information

URL:

www.avantyxpharma.com

Division Name:

AVANTYX, LLC

Division Number:

AVANTYX PH

Activation Date:

2024-11-20

Initial Registration Date:

2020-04-21

Events

Event Type	Filed Date	Value	Description
LC NAME CHANGE	2022-03-25	AVANTYX, LLC	-
REGISTERED AGENT ADDRESS CHANGED	2022-03-17	7901 SW 176th St, Palmetto Bay, FL 33157	-
CHANGE OF MAILING ADDRESS	2021-01-28	1951 NW 7TH AVENUE, MIAMI, FL 33136	-

Documents

Name	Date
ANNUAL REPORT	2025-01-09
ANNUAL REPORT	2024-02-01
ANNUAL REPORT	2023-04-03
LC Name Change	2022-03-25
ANNUAL REPORT	2022-03-17
ANNUAL REPORT	2021-01-28
Florida Limited Liability	2020-01-24

USAspending Awards / Financial Assistance

Date:

2021-09-09

Link:

View on USAspending

Awarding Agency Name:

Department of Health and Human Services

Transaction Description:

ANALYZING THE EFFICACY OF MMP-13 INHIBITORS IN THE TREATMENT OF CIPN - PROJECT SUMMARY THE GOAL OF THIS PROJECT IS TO ESTABLISH AN EFFECTIVE DRUG CANDIDATE TO TREAT CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN). THE NATIONAL CANCER INSTITUTE ESTIMATES THAT APPROXIMATELY 400,000 (OR ~60-70%) OF PATIENTS UNDERGOING CHEMOTHERAPY SUFFER FROM CIPN. THESE PATIENTS MAY NEED TO TERMINATE CHEMOTHERAPY TREATMENT IF EXPERIENCING SYMPTOMS, SUCH AS NUMBNESS, PAIN, TEMPERATURE SENSITIVITY, OR TINGLING. CANCER SURVIVORS FURTHERMORE OFTEN HAVE TO LIVE WITH CIPN FOR THE REST OF THEIR LIVES. TO DATE ARE NO TREATMENTS AVAILABLE WITH WHICH TO TACKLE THIS PROBLEM. CIPN COSTS THE HEALTHCARE SYSTEM UPWARD OF $13B ANNUALLY FOR LONG-TERM CARE OF THE PATIENTS. THUS, THERE IS A SIGNIFICANT CLINICAL AND ECONOMICAL NEED TO DEVELOP DRUG THERAPIES. AVANTYX PHARMACEUTICALS, LLC HAS IDENTIFIED A NEW COMPOUND TARGETING THE MATRIX-METALLOPROTEINASE 13 (MMP-13), WHICH WAS SHOWN TO PROMOTE THE DEGENERATION OF SENSORY NERVE ENDINGS IN ANIMAL MODELS FOR CIPN INDUCED BY PACLITAXEL TREATMENT. THE KEY FOCUS OF THIS PHASE I PROJECT IS TO CHARACTERIZE A NOVEL MMP-13 INHIBITOR FOR ITS BIOAVAILABILITY, EFFICACY, SPECIFICITY, AND TOXICITY IN A RAT MODEL OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY, WHICH IS FOLLOWING STUDIES IN WHICH WE ESTABLISHED THE EFFICACY OF THIS INHIBITOR IN ZEBRAFISH. KEY GOALS ARE TO ESTABLISH PARAMETERS, SUCH AS OPTIMAL ROUTE OF ADMINISTRATION (ORAL OR TOPICAL), OPTIMAL DOSING, AND TARGET SPECIFICITY, WHICH IS NECESSARY TO PROCEED TO FURTHER DRUG DEVELOPMENT STUDIES IN PHASE II.

Obligated Amount:

355723.00

Face Value Of Loan:

0.00

Total Face Value Of Loan:

0.00

Date of last update: 01 Jun 2025

Sources: Florida Department of State